SCHEMBL6020310

SCHEMBL6020310

N#CCNC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)Cc1c[nH]c2ccccc12

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSL P07711 3/20 0.77
CTSS P25774 2/20 0.71
CTSK P43235 1/20 0.71
TACR1 P25103 1/20 0.60
CTSB P07858 1/20 0.58
BRS3 P32247 2/20 0.56
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
MMP8 P22894 1/20 0.55
ACE P12821 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
ECE1 P42892 2/20 0.54
KCNT1 Q5JUK3 1/20 0.54
TACR3 P29371 1/20 0.54
P2RY14 Q15391 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021405 0.94 CTSL (0.68) CTSLCTSSCTSKTACR1CTSB
SCHEMBL6020812 0.90 CTSL (0.63) CTSLCTSSCTSKTACR1CTSB
SCHEMBL6021059 0.90 CTSL (0.63) CTSLCTSSCTSKTACR1CTSB
SCHEMBL6020071 0.89 CTSL (0.74) CTSLCTSSCTSKTACR1BRS3
SCHEMBL6020042 0.89 CTSL (0.62) CTSLCTSSCTSKTACR1BRS3
SCHEMBL6021334 0.89 CTSL (0.74) CTSLCTSSCTSKTACR1BRS3
SCHEMBL6185639 0.89 CTSL (0.62) CTSLCTSSCTSKCTSBMMP2
SCHEMBL6021141 0.89 CTSL (0.62) CTSLCTSSCTSKTACR1CTSB
SCHEMBL6021325 0.89 CTSL (0.74) CTSLCTSSCTSKTACR1BRS3
SCHEMBL6021157 0.89 CTSL (0.62) CTSLCTSSCTSKTACR1CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US claimed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP claimed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO claimed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 WO claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US disclosed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP disclosed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 CTSL 2274/4885CTSS 2720/4885CTSK 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.